Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases
- PMID: 28438872
- PMCID: PMC5461454
- DOI: 10.21873/invivo.11076
Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases
Abstract
Background: Surgical resection is currently considered the only potentially curative option as a treatment strategy of colorectal liver metastases (CRLM). However, the criteria for selection of resectable CRLM are not clear. The aim of this study was to confirm a new prognostic indicator of CRLM after hepatic resection.
Patients and methods: One hundred thirty nine patients who underwent initial surgical resection from 1994 to 2015 were investigated retrospectively. Prognostic factors of overall survival including the product of maximum diameter and number of metastases (MDN) were analyzed.
Results: Primary tumor differentiation, vessel invasion, lymph node (LN) metastasis, non-optimally resectable metastases, H score, grade of liver metastases, resection with non-curative intent and MDN were found to be prognostic factors of overall survival (OS). In multivariate analyses of clinicopathological features associated with OS, MDN and non-curative intent were independent prognostic factors. Patients with MDN ≥30 had shown significantly poorer prognosis than patients with MDN <30 in OS and relapse-free survival (RFS).
Conclusion: MDN ≥30 is an independent prognostic factor of survival in patients with CRLM and optimal surgical criterion of hepatectomy for CRLM.
Keywords: Colorectal liver metastases; MDN; prognostic factor.
Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Figures
Similar articles
-
Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study.Dig Surg. 2013;30(4-6):293-301. doi: 10.1159/000354310. Epub 2013 Aug 21. Dig Surg. 2013. PMID: 23969407
-
Lymphatic Invasion is an Independent Adverse Prognostic Factor in Patients with Colorectal Liver Metastasis.Ann Surg Oncol. 2015 Dec;22 Suppl 3:S638-45. doi: 10.1245/s10434-015-4562-8. Epub 2015 May 19. Ann Surg Oncol. 2015. PMID: 25986865 Free PMC article.
-
The prognostic value of the primary tumor’s nodal status after surgery for colorectal liver metastases in the era of effective systemic therapy.Dig Surg. 2015;32(3):208-16. doi: 10.1159/000381755. Dig Surg. 2015. PMID: 25896431
-
[Diagnosis and treatment of colorectal liver metastases - workflow].Zentralbl Chir. 2008 Jun;133(3):267-84. doi: 10.1055/s-2008-1076796. Zentralbl Chir. 2008. PMID: 18563694 Review. German.
-
Primary tumor location and the prognosis of patients after local treatment of colorectal liver metastases: a systematic review and meta-analysis.HPB (Oxford). 2020 Mar;22(3):351-357. doi: 10.1016/j.hpb.2019.10.003. Epub 2019 Oct 24. HPB (Oxford). 2020. PMID: 31668753
Cited by
-
The Usefulness of Total Tumor Volume as a Prognostic Factor and in Selecting the Optimal Treatment Strategy of Chemotherapeutic Intervention in Patients with Colorectal Liver Metastases.Ann Surg Oncol. 2023 Oct;30(11):6603-6610. doi: 10.1245/s10434-023-13746-3. Epub 2023 Jun 29. Ann Surg Oncol. 2023. PMID: 37386304
-
Total tumour volume as a prognostic factor in patients with resectable colorectal cancer liver metastases.BJS Open. 2020 Jun;4(3):456-466. doi: 10.1002/bjs5.50280. Epub 2020 Apr 11. BJS Open. 2020. PMID: 32277807 Free PMC article.
-
Complications associated with iliosacral lymphadenectomy in dogs with metastatic apocrine gland anal sac adenocarcinoma.Can Vet J. 2022 Sep;63(9):929-934. Can Vet J. 2022. PMID: 36060485 Free PMC article.
-
Prognostic value of preoperative carcinoembryonic antigen/tumor size in rectal cancer.World J Gastroenterol. 2019 Sep 7;25(33):4945-4958. doi: 10.3748/wjg.v25.i33.4945. World J Gastroenterol. 2019. PMID: 31543685 Free PMC article.
References
-
- Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26(4):702–708. - PubMed
-
- Lam VW, Pang T, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of repeat hepatectomy for recurrent colorectal liver metastases. J Gastrointest Surg. 2013;17(7):1312–1321. - PubMed
-
- Umehara M, Umehara Y, Takahashi K, Murata A, Nishikawa S, Matsuzaka M, Tanaka R, Morita T. Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer. Anticancer research. 2016;36(4):1949–1954. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical